

# CALCITONIN GENE-RELATED PEPTIDE (CGRP) PRIOR AUTHORIZATION REQUEST PRESCRIBER FAX FORM

**Only the prescriber may complete this form. This form is for prospective, concurrent, and retrospective reviews.**

**The following documentation is REQUIRED.** Incomplete forms will be returned for additional information. For formulary information please visit [www.myprime.com](http://www.myprime.com). Start saving time today by filling out this form electronically. Visit [covermymeds.com](http://covermymeds.com) to begin using this free service.

**What is the priority level of this request?**

- Standard review
- Expedited/Urgent review – prescriber certifies that waiting for a standard review could seriously harm the patient’s life, health or ability to regain maximum function

**Today’s Date:** \_\_\_\_\_

**PATIENT AND INSURANCE INFORMATION**

**Date of Service (if differs from Today’s Date):** \_\_\_\_\_

Patient Name (First):	Last:	M:	DOB (mm/dd/yyyy):
Patient Address:	City, State, Zip:	Patient Telephone:	
Member ID Number:		Group Number:	

**PRESCRIBER/CLINIC INFORMATION**

Prescriber Name:	Prescriber NPI#:	Specialty:	Contact Name:
Clinic Name:	Clinic Address:		
City, State, Zip:	Phone #:	Secure Fax #:	

**PLEASE ATTACH ANY ADDITIONAL INFORMATION THAT SHOULD BE CONSIDERED WITH THIS REQUEST**

Patient’s Diagnosis: <input type="checkbox"/> Migraine prophylaxis <input type="checkbox"/> Treatment of episodic cluster headache <input type="checkbox"/> Acute migraine treatment <input type="checkbox"/> Other (ICD code and description): _____	
Medication Requested:	Strength:
Dosing Schedule:	Quantity per Month:
<b>For all requests:</b> 1. Is the patient currently treated with the requested agent? ..... <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, was the treatment started on samples? ..... <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, is the patient at risk if therapy is changed? ..... <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, please specify risk: _____ _____	
2. Does the patient have any FDA labeled contraindications to the requested agent? ..... <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, please specify contraindication(s): _____ _____	
3. Is the patient’s age within FDA labeling for the requested indication for the requested agent? ..... <input type="checkbox"/> Yes <input type="checkbox"/> No If no, is there support for using the requested agent for the patient’s age for the requested indication? ..... <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, please provide supporting information: _____ _____	
4. Has medication overuse headache been ruled out? ..... <input type="checkbox"/> Yes <input type="checkbox"/> No	
5. Please list all reasons for selecting the requested agent, strength, dosing schedule, and quantity over alternatives (e.g., contraindications, allergies, history of adverse drug reactions to alternatives, lower dose has been tried, information supporting dose over FDA max). <b>Please note, documentation may be required:</b> _____ _____ _____ _____	
<b>Please continue to the next page.</b>	

Patient Name (First):	Last:	M:	DOB (mm/dd/yyyy):
-----------------------	-------	----	-------------------

6. Has the patient been diagnosed with stage four advanced, metastatic cancer and the requested agent is being used to treat the cancer? .....  Yes  No
- If yes, is the use of the requested agent consistent with best practices for the treatment of stage four advanced, metastatic cancer, or an associated condition; supported by peer-reviewed, evidence-based literature; and approved by the United States Food and Drug Administration? .....  Yes  No
- If no, has the patient been diagnosed with stage four advanced, metastatic cancer and the requested agent is being used to treat an associated condition related to stage four advanced metastatic cancer? .....  Yes  No
- If yes, is the use of the requested agent consistent with best practices for the treatment of stage four advanced, metastatic cancer, or an associated condition; supported by peer-reviewed, evidence-based literature; and approved by the United States Food and Drug Administration? .....  Yes  No

**For acute migraine treatment requests:**

7. Has the patient tried and had an inadequate response to ONE triptan agent? .....  Yes  No
- If no, does the patient have an intolerance or hypersensitivity to ONE triptan agent? .....  Yes  No
- If no, does the patient have an FDA labeled contraindication to ALL triptan agents? .....  Yes  No
8. Will the patient be using the requested agent in combination with another acute migraine therapy (i.e., 5HT-1F, acute use CGRP, ergotamine) for the requested indication? .....  Yes  No
- If yes, please specify: \_\_\_\_\_
- If yes, is the other acute migraine therapy agent Nurtec ODT? .....  Yes  No
- If yes, has the patient been prescribed Nurtec ODT for acute migraine treatment? .....  Yes  No
9. Does the requested quantity (dose) exceed the maximum FDA labeled dose for the requested indication? .....  Yes  No
- If yes, is the patient currently being treated with a migraine prophylactic medication (i.e., anticonvulsants [i.e., divalproex, valproate, topiramate], beta blockers [i.e., atenolol, metoprolol, nadolol, propranolol, timolol], tricyclic antidepressants [i.e., amitriptyline, nortriptyline], SNRIs [i.e., venlafaxine, duloxetine], candesartan, prophylactic use CGRP [e.g., Aimovig, AJOVY, Emgality, Nurtec ODT, QULIPTA, Vyepiti], or onabotulinumtoxinA [Botox])? .....  Yes  No
- If yes, please specify: \_\_\_\_\_
- \_\_\_\_\_
- If no, does the patient have an intolerance or hypersensitivity to therapy with migraine prophylactic medication (i.e., anticonvulsants [i.e., divalproex, valproate, topiramate], beta blockers [i.e., atenolol, metoprolol, nadolol, propranolol, timolol], tricyclic antidepressants [i.e., amitriptyline, nortriptyline], SNRIs [i.e., venlafaxine, duloxetine], candesartan, prophylactic use CGRP [e.g., Aimovig, AJOVY, Emgality, Nurtec ODT, QULIPTA, Vyepiti], onabotulinumtoxinA [Botox])? .....  Yes  No
- If yes, please explain intolerance/hypersensitivity: \_\_\_\_\_
- \_\_\_\_\_
- If no, does the patient have an FDA labeled contraindication to ALL migraine prophylactic medications (i.e., anticonvulsants [i.e., divalproex, valproate, topiramate], beta blockers [i.e., atenolol, metoprolol, nadolol, propranolol, timolol], tricyclic antidepressants [i.e., amitriptyline, nortriptyline], SNRIs [i.e., venlafaxine, duloxetine], candesartan, prophylactic use CGRP [e.g., Aimovig, AJOVY, Emgality, Nurtec ODT, QULIPTA, Vyepiti], AND onabotulinumtoxinA [Botox])? ....  Yes  No
- If yes, please provide supporting information: \_\_\_\_\_
- \_\_\_\_\_

**For migraine prophylaxis requests:**

10. Does the patient have chronic migraine (defined as having had at least 15 headache days per month of migraine-like or tension-like headache for a minimum of 3 months) .....  Yes  No
- If yes, has the patient had at least 8 migraine headache days per month for a minimum of 3 months? .....  Yes  No
- If no, does the patient have episodic migraine (defined as having 4-14 monthly migraine days)? .....  Yes  No
11. Will the patient be using the requested agent in combination with another prophylactic use CGRP? .....  Yes  No
- If yes, please specify: \_\_\_\_\_
- If yes, is the other prophylactic use CGRP Nurtec ODT? .....  Yes  No
- If yes, has the patient been prescribed Nurtec ODT for migraine prophylaxis? .....  Yes  No

**Please continue to the next page.**

Patient Name (First):	Last:	M:	DOB (mm/dd/yyyy):
-----------------------	-------	----	-------------------

**For treatment of episodic cluster headache requests:**

12. Has the patient had at least 5 cluster headache attacks? .....  Yes  No
13. Has the patient had at least two cluster periods lasting 7-365 days? .....  Yes  No
14. Are the patient's cluster periods separated by a pain-free remission period of greater than or equal to 3 months? .....  Yes  No
15. Has the patient tried and had an inadequate response to ONE prerequisite agent (i.e., verapamil, melatonin, corticosteroids, topiramate, lithium)? .....  Yes  No
- If no, does the patient have an intolerance or hypersensitivity to ONE prerequisite agent (i.e., verapamil, melatonin, corticosteroids, topiramate, lithium)? .....  Yes  No
- If no, does the patient have an FDA labeled contraindication to ALL prerequisite agents (i.e., verapamil, melatonin, corticosteroids, topiramate, lithium)? .....  Yes  No

**For renewal requests:**

16. Has the patient had clinical benefit with the requested agent? .....  Yes  No

**Please fax or mail this form to:**

Prime Therapeutics LLC  
 Clinical Review Department  
 2900 Ames Crossing Road  
 Eagan, MN 55121

**TOLL FREE**

**Phone:**

**BCBSIL: 800.285.9426**  
**BCBSMT: 888.723.7443**  
**BCBSNM: 800.544.1378**  
**BCBSOK: 800.991.5643**  
**BCBSTX: 800.289.1525**

**Fax: 877.243.6930**

**CONFIDENTIALITY NOTICE:** This communication is intended only for the use of the individual entity to which it is addressed, and may contain information that is privileged or confidential. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please return the original message to Prime Therapeutics via U.S. Mail. Thank you for your cooperation.